Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.41 |
| ▸ | SRC | P12931 | 5/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | USP7 | Q93009 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | ABL2 | P42684 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23897580 | 1.00 | PIK3CD (0.41) | PIK3CDSRCEGFRUSP7ABL1 | |
| SCHEMBL515281 | 0.87 | TGFBR1 (0.47) | PIK3CDSRCEGFRUSP7BCHE | |
| SCHEMBL515778 | 0.87 | TGFBR1 (0.47) | PIK3CDSRCEGFRUSP7BCHE | |
| SCHEMBL23882273 | 0.86 | FGFR1 (0.38) | — | |
| SCHEMBL17394745 | 0.85 | GPR119 (0.46) | USP7TGFBR1GPR119 | |
| SCHEMBL514832 | 0.83 | JAK3 (0.41) | PIK3CDUSP7BCHEHTR6TGFBR1 | |
| SCHEMBL31637406 | 0.82 | GPR119 (0.38) | PIK3CDSRCEGFRTGFBR1GPR119 | |
| SCHEMBL31637279 | 0.82 | GPR119 (0.38) | PIK3CDSRCEGFRTGFBR1GPR119 | |
| SCHEMBL23897651 | 0.82 | GPR119 (0.41) | PIK3CDGPR119 | |
| SCHEMBL9950465 | 0.80 | SRC (0.54) | PIK3CDSRCEGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| EP-4126874-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2023-02-08 | — | — | EP | disclosed |
| US-20220363683-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780843-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | PIK3CD 2674/4885SRC 942/4885EGFR 719/4885 |
| US-20220363683-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | PIK3CD 2674/4885SRC 942/4885EGFR 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.